A standardized pathology report for gastric cancer: 2nd edition

키워드

참고문헌 (181)

1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
3. 김우호, "위암 병리보고서 기재사항 표준화", Journal of Pathology and Translational Medicine, 39(2), pp.106~113 (2005), 대한병리학회
4. World Health Organization, "WHO classification of tumours: digestive system tumours" (2019), World Health Organization
5. Guideline Committee of the Korean Gastric Cancer Association, "Korean Practice Guideline for Gastric Cancer 2018; Evidence-based, Multi-disciplinary Approach", Journal of Gastric Cancer, 19(1), pp.1~48 (2019), 대한위암학회[DOI]
6. Muro K, "Pembrolizumab for patients with PD-L1-positive advanced gastric cancer(KEYNOTE-012) : a multicentre, open-label, phase 1b trial", Lancet Oncol, 17, pp.717~726 (2016)
7. Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
8. Amin MB, "AJCC cancer staging manual" (2017), Springer
9. Japanese Gastric Cancer Association, "Japanese classification of gastric carcinoma: 3rd English edition", Gastric Cancer, 14, pp.101~112 (2011)
10. Fritz A, "International Classification of Diseases for Oncology (ICD-O)" (2013), International Agency for Research on Cancer
11. "Protocol for the examination of specimens from patients with carcinoma of the stomach" (2020)[URL]
12. Shi C, "Data set for reporting carcinoma of the stomach in gastrectomy", Arch Pathol Lab Med, 146, pp.1072~1083 (2022)
13. Cunningham D, "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer", N Engl J Med, 355, pp.11~20 (2006)
14. Zhang X, "Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3randomised controlled trial", Lancet Oncol, 22, pp.1081~1092 (2021)
15. Kang YK, "PRODIGY : a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer", J Clin Oncol, 39, pp.2903~2913 (2021)
16. Langer R, "Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy", Virchows Arch, 472, pp.175~186 (2018)
17. Mandard AM, "Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma : clinicopathologic correlations", Cancer, 73, pp.2680~2686 (1994)
18. Dworak O, "Pathological features of rectal cancer after preoperative radiochemotherapy", Int J Colorectal Dis, 12, pp.19~23 (1997)
19. Becker K, "Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy", Cancer, 98, pp.1521~1530 (2003)
20. Mirza A, "Assessment of histopathological response in gastric and gastro-oesophageal junction adenocarcinoma following neoadjuvant chemotherapy : which scoring system to use?", ISRN Pathol, 2012, pp.519351~ (2012)
21. Karamitopoulou E, "Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy : comparison of 2 commonly used scoring approaches", Am J Surg Pathol, 38, pp.1551~1556 (2014)
22. 김백희, "Standardized Pathology Report for Colorectal Cancer, 2nd Edition", Journal of Pathology and Translational Medicine, 54(1), pp.1~19 (2020), 대한병리학회[DOI]
23. Tsekrekos A, "Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes", Hum Pathol, 116, pp.94~101 (2021)
24. Davies AR, "Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma", Br J Surg, 105, pp.1639~1649 (2018)
25. Reim D, "Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas", J Pathol Clin Res, 6, pp.263~272 (2020)
26. Smyth EC, "Effect of pathologic tumor response and nodal status on survival in the Medical Research Council adjuvant gastric infusional chemotherapy Trial", J Clin Oncol, 34, pp.2721~2727 (2016)
27. Koh YW, "Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy", Am J Surg Pathol, 37, pp.1022~1029 (2013)
28. Veronese N, "Extranodal extension of nodal metastases is a poor prognostic indicator in gastric cancer : a systematic review and meta-analysis", J Gastrointest Surg, 20, pp.1692~1698 (2016)
29. Lee IS, "Impact of extranodal extension on prognosis in lymph node-positive gastric cancer", Br J Surg, 101, pp.1576~1584 (2014)
30. Lee IS, "Prognostic impact of extranodal extension in stage 1B gastric carcinomas", Surg Oncol, 27, pp.299~305 (2018)
31. Araki I, "Prognostic impact of venous invasion in stage IB node-negative gastric cancer", Gastric Cancer, 18, pp.297~305 (2015)
32. Takeuchi A, "Venous invasion is a risk factor for recurrence of pT1 gastric cancer with lymph node metastasis", J Gastrointest Surg, 26, pp.757~763 (2022)
33. Nishibeppu K, "Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer", BMC Cancer, 18, pp.108~ (2018)
34. Liebig C, "Perineural invasion in cancer : a review of the literature", Cancer, 115, pp.3379~3391 (2009)
35. Hanaoka N, "Mixedhistologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis : feasibility of endoscopic submucosal dissection", Endoscopy, 41, pp.427~432 (2009)
36. Takizawa K, "Risk of lymph node metastases from intramucosal gastric cancer in relation to histological types : how to manage the mixed histological type for endoscopic submucosal dissection", Gastric Cancer, 16, pp.531~536 (2013)
37. Lee JH, "Risk of lymph node metastasis in differentiated type mucosal early gastric cancer mixed with minor undifferentiated type histology", Ann Surg Oncol, 22, pp.1813~1819 (2015)
38. Sekiguchi M, "Risk stratification and predictive risk-scoring model for lymph node metastasis in early gastric cancer", J Gastroenterol, 51, pp.961~970 (2016)
39. Seo HS, "Mixed histology is a risk factor for lymph node metastasis in early gastric cancer", J Surg Res, 236, pp.271~277 (2019)
40. Horiuchi Y, "Feasibility of further expansion of the indications for endoscopic submucosal dissection in undifferentiated-type early gastric cancer", Gastric Cancer, 23, pp.285~292 (2020)
41. Ha TK, "Indication for endoscopic mucosal resection in early signet ring cell gastric cancer", Ann Surg Oncol, 15, pp.508~513 (2008)
42. Kim BS, "Signet ring cell type and other histologic types : differing clinical course and prognosis in T1 gastric cancer", Surgery, 155, pp.1030~1035 (2014)
43. Guo CG, "Risk factors for lymph node metastasis in early gastric cancer with signet ring cell carcinoma", J Gastrointest Surg, 19, pp.1958~1965 (2015)
44. Huh CW, "Signet ring cell mixed histology may show more aggressive behavior than other histologies in early gastric cancer", J Surg Oncol, 107, pp.124~129 (2013)
45. Lee IS, "Applicability of endoscopic submucosal dissection for undifferentiated early gastric cancer : Mixed histology of poorly differentiated adenocarcinoma and signet ring cell carcinoma is a worse predictive factor of nodal metastasis", Surg Oncol, 26, pp.8~12 (2017)
46. Kim YH, "Histologic purity of signet ring cell carcinoma is a favorable risk factor for lymph node metastasis in poorly cohesive, submucosa-invasive early gastric carcinoma", Gastric Cancer, 20, pp.583~590 (2017)
47. Chu Y, "Predictors of lymph node metastasis and differences between pure and mixed histologic types of early gastric signet-ring cell carcinomas", Am J Surg Pathol, 44, pp.934~942 (2020)
48. Japanese Gastric Cancer Society, "Regulations for the treatment of gastric cancer" (2017), Kanehara Publishing
49. Kim JY, "Lymph node metastasis in early gastric cancer : evaluation of a novel method for measuring submucosal invasion and development of a nodal predicting index", Hum Pathol, 44, pp.2829~2836 (2013)
50. Ma DW, "The suggestion of revised criteria for endoscopic resection of differentiated-type submucosal gastric cancer", Ann Surg Oncol, 27, pp.795~801 (2020)
51. Choi JY, "Identifying predictors of lymph node metastasis after endoscopic resection in patients with minute submucosal cancer of the stomach", Surg Endosc, 29, pp.1476~1483 (2015)
52. Gotoda T, "Incidence of lymph node metastasis from early gastric cancer : estimation with a large number of cases at two large centers", Gastric Cancer, 3, pp.219~225 (2000)
53. 박성민, "Can Endoscopic Ulcerations in Early Gastric Cancer Be Clearly Defined before Endoscopic Resection? A Survey among Endoscopists", Clinical Endoscopy, 50(5), pp.473~478 (2017), 대한소화기내시경학회
54. Kim JM, "Pre- and post-ESD discrepancies in clinicopathologic criteria in early gastric cancer: the NECA-Korea ESD for Early Gastric Cancer Prospective Study (NKeep)", Gastric Cancer, 19, pp.1104~1113 (2016)
55. Yabuuchi Y, "Discrepancy between endoscopic and pathological ulcerative findings in clinical intramucosal early gastric cancer", Gastric Cancer, 24, pp.691~700 (2021)
56. Shimoda T, "Histological features of peptic ulceration and biopsy scar of gastric ESD specimen", Stomach Intestine, 48, pp.16~24 (2013)
57. Japanese Gastric Cancer Association, "Japanese gastric cancer treatment guidelines 2018 (5th edition)", Gastric Cancer, 24, pp.1~21 (2021)
58. Takizawa K, "A nonrandomized, singlearm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer : Japan Clinical Oncology Group study (JCOG1009", 1010), 2021, pp.24, 479~491
59. Hatta W, "A scoring system to stratify curability after endoscopic submucosal dissection for early gastric cancer : "eCura system"", Am J Gastroenterol, 112, pp.874~881 (2017)
60. Uesugi N, "Clinicopathological and molecular stability and methylation analyses of gastric papillary adenocarcinoma", Pathology, 49, pp.596~603 (2017)
61. Lee HJ, "Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach : is it really safe?", Gastric Cancer, 20, pp.978~986 (2017)
62. Min BH, "Lymphovascular invasion and lymph node metastasis rates in papillary adenocarcinoma of the stomach : implications for endoscopic resection", Gastric Cancer, 21, pp.680~688 (2018)
63. Yasuda K, "Papillary adenocarcinoma of the stomach", Gastric Cancer, 3, pp.33~38 (2000)
64. Yu H, "Worse prognosis in papillary, compared to tubular, early gastric carcinoma", J Cancer, 8, pp.117~123 (2017)
65. Kawamura H, "A clinicopathologic study of mucinous adenocarcinoma of the stomach", Gastric Cancer, 4, pp.83~86 (2001)
66. Lee HH, "Undifferentiated-type gastric adenocarcinoma : prognostic impact of three histological types", World J Surg Oncol, 10, pp.254~ (2012)
67. Nakamura K, "Clinicopathological characteristics and prognosis of poorly cohesive cell subtype of gastric cancer", Int J Clin Oncol, 27, pp.512~519 (2022)
68. Roviello F, "Signet ring cell percentage in poorly cohesive gastric cancer patients : a potential novel predictor of survival", Eur J Surg Oncol, 48, pp.561~569 (2022)
69. Garcia-Pelaez J, "Histological and mutational profile of diffuse gastric cancer : current knowledge and future challenges", Mol Oncol, 15, pp.2841~2867 (2021)
70. Kwon CH, "Gastric poorly cohesive carcinoma : a correlative study of mutational signatures and prognostic significance based on histopathological subtypes", Histopathology, 72, pp.556~568 (2018)
71. Mariette C, "Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma", Gastric Cancer, 22, pp.1~9 (2019)
72. Han JP, "Long-term outcomes of early gastric cancer diagnosed as mixed adenocarcinoma after endoscopic submucosal dissection", J Gastroenterol Hepatol, 30, pp.316~320 (2015)
73. 박형규, "Mixed Carcinoma as an Independent Prognostic Factor in Submucosal Invasive Gastric Carcinoma", Journal of Korean Medical Science, 31(6), pp.866~872 (2016), 대한의학회
74. Horiuchi Y, "Undifferentiated-type predominant mixed-type early gastric cancer is a significant risk factor for requiring additional surgeries after endoscopic submucosal dissection", Sci Rep, 10, pp.6748~ (2020)
75. Ozeki Y, "Mixed histology poses a greater risk for noncurative endoscopic resection in early gastric cancers regardless of the predominant histologic types", Eur J Gastroenterol Hepatol, 32, pp.186~193 (2021)
76. Shin DH, "Clinicopathologic features of early gastric carcinoma with lymphoid stroma and feasibility of endoscopic submucosal dissection", Surg Endosc, 31, pp.4156~4164 (2017)
77. Iwasaki K, "Postoperative outcomes of gastric carcinoma with lymphoid stroma", World J Surg Oncol, 18, pp.102~ (2020)
78. Huh CW, "Clinicopathologic features of gastric carcinoma with lymphoid stroma in early gastric cancer", J Surg Oncol, 114, pp.769~772 (2016)
79. Inagawa S, "Hepatoid adenocarcinoma of the stomach", Gastric Cancer, 4, pp.43~52 (2001)
80. Roh JH, "Micropapillary carcinoma of stomach : a clinicopathologic and immunohistochemical study of 11 cases", Am J Surg Pathol, 34, pp.1139~1146 (2010)
81. Fujita T, "Clinicopathological features of stomach cancer with invasive micropapillary component", Gastric Cancer, 15, pp.179~187 (2012)
82. Benedict MA, "Gastric adenocarcinoma of the fundic gland type : update and literature review", Am J Clin Pathol, 149, pp.461~473 (2018)
83. Miyazawa M, "Gastric adenocarcinoma of the fundic gland(chief cell-predominant type) : a review of endoscopic and clinicopathological features", World J Gastroenterol, 22, pp.10523~10531 (2016)
84. Agaimy A, "SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review", Am J Surg Pathol, 38, pp.910~920 (2014)
85. Willems S, "Gastric carcinoma with osteoclast-like giant cells and lymphoepithelioma-like carcinoma of the stomach : two of a kind?", Histopathology, 47, pp.331~333 (2005)
86. Woo HY, "Distinct expression profile of key molecules in crawling-type early gastric carcinoma", Gastric Cancer, 20, pp.612~619 (2017)
87. Okamoto N, "“Crawling-type” adenocarcinoma of the stomach: a distinct entity preceding poorly differentiated adenocarcinoma", Gastric Cancer, 16, pp.220~232 (2013)
88. Ushiku T, "Oxyntic gland neoplasm of the stomach : expanding the spectrum and proposal of terminology", Mod Pathol, 33, pp.206~216 (2020)
89. Tsuji Y, "Risk for lymph node metastasis in Epstein-Barr virus-associated gastric carcinoma with submucosal invasion", Dig Endosc, 33, pp.592~597 (2021)
90. Lauren P, "The two histological main types of gastric carcinoma : diffuse and so-called intestinal-type carcinoma : an attempt at a histo-clinical classification", Acta Pathol Microbiol Scand, 64, pp.31~49 (1965)
91. Park DY, "Adenomatous and foveolar gastric dysplasia : distinct patterns of mucin expression and background intestinal metaplasia", Am J Surg Pathol, 32, pp.524~533 (2008)
92. Choi WT, "Gastric pyloric gland adenoma : a multicentre clinicopathological study of 67 cases", Histopathology, 72, pp.1007~1014 (2018)
93. 김준미, "Inter-observer Reproducibility in the Pathologic Diagnosis of Gastric Intraepithelial Neoplasia and Early Carcinoma in Endoscopic Submucosal Dissection Specimens: A Multi-center Study", Cancer Research and Treatment, 51(4), pp.1568~1577 (2019), 대한암학회
94. Kim JM, "Diagnosis of gastric epithelial neoplasia : dilemma for Korean pathologists", World J Gastroenterol, 17, pp.2602~2610 (2011)
95. Watanabe Y, "Intraglandular necrotic debris in gastric biopsy and surgical specimens", Ann Diagn Pathol, 5, pp.141~147 (2001)
96. Choi IJ, "Helicobacter pylori therapy for the prevention of metachronous gastric cancer", N Engl J Med, 378, pp.1085~1095 (2018)
97. Ono H, "Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer(second edition)", Dig Endosc, 33, pp.4~20 (2021)
98. Shitara K, "Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer", N Engl J Med, 382, pp.2419~2430 (2020)
99. "FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas" (2021)[URL]
100. Ajani JA, "Gastric cancer, version 2. 2022, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 20, pp.167~192 (2022)
101. Hofmann M, "Assessment of a HER2 scoring system for gastric cancer : results from a validation study", Histopathology, 52, pp.797~805 (2008)
102. Ahn S, "Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens", Oncotarget, 6, pp.38372~38380 (2015)
103. 이혜승, "Molecular Testing for Gastrointestinal Cancer", Journal of Pathology and Translational Medicine, 51(2), pp.103~121 (2017), 대한병리학회[DOI]
104. Bartley AN, "HER2 testing and clinical decision making in gastroesophageal adenocarcinoma:guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology", J Clin Oncol, 35, pp.446~464 (2017)
105. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
106. Van Cutsem E, "HER2 screening data from ToGA : targeting HER2 in gastric and gastroesophageal junction cancer", Gastric Cancer, 18, pp.476~484 (2015)
107. Tsapralis D, "Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology", World J Gastroenterol, 18, pp.150~155 (2012)
108. Liu W, "HER-2", neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients, 2012, pp.46, e31~e37
109. Lee HE, "Clinical significance of intratumoral HER2 heterogeneity in gastric cancer", European Journal of Cancer, 49, pp.1448~1457 (2013)
110. Kim MA, "Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma", Histopathology, 59, pp.822~831 (2011)
111. Peng Z, "HER2 discordance between paired primary gastric cancer and metastasis : a meta-analysis", Chin J Cancer Res, 27, pp.163~171 (2015)
112. Kim JH, "Comparative analysis of protein expressions in primary and metastatic gastric carcinomas", Hum Pathol, 40, pp.314~322 (2009)
113. Fusco N, "HER2 in gastric cancer : a digital image analysis in pre-neoplastic, primary and metastatic lesions", Mod Pathol, 26, pp.816~824 (2013)
114. Geng Y, "Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer", Int J Clin Oncol, 19, pp.303~311 (2014)
115. Kochi M, "Differing deregulation of HER2in primary gastric cancer and synchronous related metastatic lymph nodes", Diagn Pathol, 8, pp.191~ (2013)
116. Ieni A, "HER2 status in premalignant, early, and advanced neoplastic lesions of the stomach", Dis Markers, 2015, pp.234851~ (2015)
117. Zhao W, "Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer", Ther Adv Med Oncol, 13, pp.17588359211012982~ (2021)
118. Garrido-Ramos MA, "Satellite DNA : an evolving topic", Genes (Basel), 8, pp.230~ (2017)
119. Luchini C, "ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1", PD-L1 expression and tumour mutational burden: a systematic review-based approach, 2019, pp.30, 1232~1243
120. Li K, "Microsatellite instability : a review of what the oncologist should know", Cancer Cell Int, 20, pp.16~ (2020)
121. Jiricny J, "Postreplicative mismatch repair", Cold Spring Harb Perspect Biol, 5, pp.a012633~ (2013)
122. Ma J, "The therapeutic significance of mutational signatures from DNA repair deficiency in cancer", Nat Commun, 9, pp.3292~ (2018)
123. Peltomaki P, "Role of DNA mismatch repair defects in the pathogenesis of human cancer", J Clin Oncol, 21, pp.1174~1179 (2003)
124. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
125. Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)
126. Setia N, "A protein and mRNA expression-based classification of gastric cancer", Mod Pathol, 29, pp.772~784 (2016)
127. Ahn S, "High-throughput protein and mRNA expression-based classification of gastric cancers can identify clinically distinct subtypes, concordant with recent molecular classifications", Am J Surg Pathol, 41, pp.106~115 (2017)
128. Choi YY, "Microsatellite instability and programmed cell death-ligand 1 expression in stage II", III gastric cancer : post hoc analysis of the CLASSIC randomized controlled study, 2019, pp.270, 309~316
129. Guastadisegni C, "Microsatellite instability as a marker of prognosis and response to therapy : a meta-analysis of colorectal cancer survival data", Eur J Cancer, 46, pp.2788~2798 (2010)
130. Kim ST, "Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer", Nat Med, 24, pp.1449~1458 (2018)
131. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
132. Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
133. Ratti M, "Microsatellite instability in gastric cancer : molecular bases, clinical perspectives, and new treatment approaches", Cell Mol Life Sci, 75, pp.4151~4162 (2018)
134. Jang M, "Microsatellite instability test using peptide nucleic acid probe-mediated melting point analysis: a comparison study", Bmc Cancer, 18, pp.1218~ (2018)
135. Murphy KM, "Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers", J Mol Diagn, 8, pp.305~311 (2006)
136. Berg KD, "Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction", J Mol Diagn, 2, pp.20~28 (2000)
137. Deschoolmeester V, "Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers", J Mol Diagn, 10, pp.154~159 (2008)
138. Shia J, "The utility of immunohistochemical detection of DNA mismatch repair gene proteins", Virchows Arch, 445, pp.431~441 (2004)
139. McCarthy AJ, "Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation", J Pathol Clin Res, 5, pp.115~129 (2019)
140. Renkonen E, "Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer", J Clin Oncol, 21, pp.3629~3637 (2003)
141. Graham RP, "Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas", Am J Surg Pathol, 39, pp.1370~1376 (2015)
142. Jansson A, "Combined deficiency of hMLH1, hMSH2, hMSH3 and hMSH6 is an independent prognostic factor in colorectal cancer", Int J Oncol, 22, pp.41~49 (2003)
143. Ruszkiewicz A, "Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours", Pathology, 34, pp.541~547 (2002)
144. Fukayama M, "Thirty years of Epstein-Barr virus-associated gastric carcinoma", Virchows Arch, 476, pp.353~365 (2020)
145. Chang MS, "Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-kappaB", J Virol, 87, pp.10515~10523 (2013)
146. Hoebe EK, "BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator", Rev Med Virol, 23, pp.367~383 (2013)
147. zur Hausen A, "Unique transcription pattern of Epstein-Barr virus(EBV)in EBV-carrying gastric adenocarcinomas : expression of the transforming BARF1 gene", Cancer Res, 60, pp.2745~2748 (2000)
148. Kang GH, "Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotypepositive gastric carcinoma", Am J Pathol, 160, pp.787~794 (2002)
149. Strong MJ, "Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity : implications for possible immune adjuvant therapy", PLoS Pathog, 9, pp.e1003341~ (2013)
150. Gu L, "PD-L1 and gastric cancer prognosis : a systematic review and meta-analysis", PLoS One, 12, pp.e0182692~ (2017)
151. Park JH, "Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer", Gastric Cancer, 19, pp.1041~1051 (2016)
152. Cheng Y, "Very low risk of lymph node metastasis in Epstein-Barr virus-associated early gastric carcinoma with lymphoid stroma", BMC Gastroenterol, 20, pp.273~ (2020)
153. Yoon CJ, "Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3", pSTAT3modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas, 2020, pp.23, 780~795
154. Lee HS, "Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with epstein-barr virus-negative carcinoma", Clin Cancer Res, 10, pp.1698~1705 (2004)
155. Longnecker RM, "Fields virology", pp.1898~1959 (2013), Lippincott Williams & Wilkins
156. Boger C, "Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations", Ann Oncol, 28, pp.1005~1014 (2017)
157. Ribas A, "Tumor immunotherapy directed at PD-1", N Engl J Med, 366, pp.2517~2519 (2012)
158. 곽윤진, "Tumor immune response and immunotherapy in gastric cancer", Journal of Pathology and Translational Medicine, 54(1), pp.20~33 (2020), 대한병리학회[DOI]
159. Fuchs CS, "Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial", JAMA Oncol, 4, pp.e180013~ (2018)
160. Shitara K, "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial", Lancet, 392, pp.123~133 (2018)
161. Janjigian YY, "First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial", Lancet, 398, pp.27~40 (2021)
162. Interpretation manual: gastric or gastroesophageal junction adenocarcinoma. PD-L1 IHC 22C3 pharmDx interpretation manual: gastric or gastroesophageal juction adenocarcinoma, "DAKO Agilent Technologies", DAKO Agilent Technologies, ~ (2018)
163. Yang JH, "Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer", Gastric Cancer, 22, pp.147~154 (2019)
164. Zhou KI, "Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy", Clin Cancer Res, 26, pp.6453~6463 (2020)
165. Son SM, "Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients", Sci Rep, 10, pp.14293~ (2020)
166. Marchio C, "ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research", Ann Oncol, 30, pp.1417~1427 (2019)
167. Catenacci DV, "Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma", J Clin Oncol, 38, pp.2418~2426 (2020)
168. Maron SB, "Targeted therapies for targeted populations : anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma", Cancer Discov, 8, pp.696~713 (2018)
169. Lee J, "Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment : the VIKTORY Umbrella Trial", Cancer Discov, 9, pp.1388~1405 (2019)
170. Smyth EC, "Genomic loss of heterozygosity and survival in the REAL3 trial", Oncotarget, 9, pp.36654~36665 (2018)
171. Nakamura Y, "Biomarker-targeted therapies for advanced-stage gastric and gastrooesophageal junction cancers : an emerging paradigm", Nat Rev Clin Oncol, 18, pp.473~487 (2021)
172. van Grieken NC, "KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West : results from a large international multicentre study", Br J Cancer, 108, pp.1495~1501 (2013)
173. Wen Z, "Case report : RAB10-ALK : a novel ALK fusion in a patient with gastric cancer", Front Oncol, 11, pp.645370~ (2021)
174. Lee J, "Identification of ROS1 rearrangement in gastric adenocarcinoma", Cancer, 119, pp.1627~1635 (2013)
175. Fancello L, "Tumor mutational burden quantification from targeted gene panels : major advancements and challenges", J Immunother Cancer, 7, pp.183~ (2019)
176. Lee KW, "Association of tumor mutational burden with efficacy of pembrolizumab+", -chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062study, 2022, pp.28, 3489~3498
177. Kang SY, "Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers", Pathol Res Pract, 233, pp.153874~ (2022)
178. Ratovomanana T, "Performance of nextgeneration sequencing for the detection of microsatellite instability in colorectal cancer with deficient DNA mismatch repair", Gastroenterology, 161, pp.814~826 (2021)
179. Ascierto PA, "Preanalytic variables and tissue stewardship for reliable next-generation sequencing (NGS) clinical analysis", J Mol Diagn, 21, pp.756~767 (2019)
180. Koh J, "Development and validation of an easy-to-implement, practical algorithm for the identification of molecular subtypes of gastric cancer : prognostic and therapeutic implications", Oncologist, 24, pp.e1321~e1330 (2019)
181. Ramos M, "Gastric cancer molecular classification and adjuvant therapy : is there a different benefit according to the subtype?", J Surg Oncol, 121, pp.804~813 (2020)

관련 논문AI추천